Pravastatin Sodium Articles

Bristol-Myers Squibb decides to split off Mead Johnson nutritional unit to concentrate on biopharma

17 November 2009

Generic drugs "saved USA $734B" since 1999, GPhA says, more than cost of TARP bank bail out

11 May 2009

Sweden's TLV rejects 1st-line use of Pfizer's Lipitor, cites "20 times" cost differential

23 February 2009

New data highlights potential new role for ARBs and statins in treatment of dementia

4 August 2008

B-MS' profit accelerates on good exchange rate

4 August 2008

Merck Serono to sell portfolio of 30 B-MS drugs in Latin America

16 June 2008

US drug spending curbed by generics

19 May 2008

Rx-to-OTC switching making comeback

21 April 2008

Doctors claim statins cause memory loss

25 February 2008

Meta-analysis in The Lancet recommends statins for all diabetics, regardless of CV risk

21 January 2008

Watson's 3rd-qtr 2007 revenue hits $594.7M

19 November 2007

Statins provide benefits after use stopped

22 October 2007

Japam's Daiichi Sankyo quietly expanding in the USA as others downsize

15 October 2007

B-MS' 2nd-qtr income up 5.8% on Plavix resurgence; future cost cuts planned

6 August 2007

Wood Mackenzie rankings show shifts among top drug firms

2 July 2007

Bristol-Myers Squibb's 1st-qtr sales and profits down, as takeover talk continues

7 May 2007

New generics pose potential shake up for sleep drugs, antihypertensives in USA

12 March 2007

B-MS swings to loss in 4th qtr due to Plavix

5 February 2007

"Smarter" prescribing of statins could save millions for NHS, says Health Dept

8 January 2007

Barr's Pliva unit approval for generic pravastatin

4 December 2006

Japan's generic drugs market expected to grow 8.8% from 2006 to 2008

27 November 2006

Daiichi Sankyo's first-half profit jumps 35.3%

13 November 2006

US pharmacy benefit management firm launches generic plans

6 November 2006

Bristol-Myers Squibb's 3rd-qtr income down 65% to $388M, as sales fall 12.5%

6 November 2006

Teva's net rockets 124% in 2nd-qtr 2006

14 August 2006

Bristol-Myers Squibb's 2nd-qtr EPS plunges on flat sales and tax increase

7 August 2006

Japan stock market week to May 15, 2006

22 May 2006

Daichii Sankyo's 2005/6 net income up 9.7%

22 May 2006

B-MS's earnings hit $714M in 1st-qtr

8 May 2006

Watson ships generic Pravachol

1 May 2006

Teva gets first FDA approval for generic Pravachol

1 May 2006

Japan stock market week to Feb 20, 2006

27 February 2006

4th-qtr 2005 sales drop 1% for B-MS, as patents lost

30 January 2006

Daiichi Sankyo: 8% half-year income rise

12 December 2005

USA

22 August 2005

One-time tax benefit drives Bristol-Myers Squibb 2nd-qtr profits up 90%

8 August 2005

Teva loses exclusivity on pravastatin, US FDA

18 July 2005

UK NICE CHD preliminary report "fails to recognize that each statin is unique:" Pfizer

27 June 2005

Sankyo's net profit leaps 11.2%, despite 1.4% sales decline on weak

6 June 2005

Statins, the next to go OTC?

30 May 2005

Japan stock market week to May 23

30 May 2005

French patent expiries to save1B euros by 2008

23 May 2005

B-MS 1st-qtr 2005 income down 36%

9 May 2005

Generics threaten maturing statin market; report

18 April 2005

Competition for Mevalotin, weak home market hit Sankyo's nine month sales

28 February 2005

Japan stock market week to February 14

21 February 2005

Cholesterol drugs "still poised for US OTC switch, despite Mevacor setback"

7 February 2005

B-MS seeks clearance for Pravachol OTC

20 December 2004

Bristol-Myers Squibb reports 16% fall in 3rd-qtr earnings, though sales rise 1%

8 November 2004

Statins to open door for more US OTC switches?

20 September 2004

Sankyo sales down but profits leap 60%

9 August 2004

Bristol-Myers Squibb reaches $300M deal in SEC litigation; reports 42% 2nd-qtr earnings drop

9 August 2004

Statins and new products benefit from global focus on lipid management

19 July 2004

FDA set to speed US Rx-OTC switches?

12 July 2004

Sankyo's full-year revenues rise 4.6%

7 June 2004

Tokyo pharma stocks - week to May 24

31 May 2004

Are statins next for OTC switching?

10 May 2004

AstraZeneca's Crestor leads the way to meeting new European LDL-C goals

5 April 2004

PROVE-IT confirms "the lower the better" hypothesis for LDL cholesterol is right

15 March 2004

Stock Commentary - New York

15 March 2004

Positive new data for AstraZeneca's Crestor

15 March 2004

Sankyo boosts full-year net forecast to 40B yen

23 February 2004

Tokyo pharma stocks - week to Feb 9

16 February 2004

20% pharma sales rise boosts B-MS profits

9 February 2004

Eisai's pravastatin generic sluggish

5 January 2004

Australia/US trade deal stumbles over PBS

15 December 2003

Boost for Pfizer's Lipitor in first head-to-head statin study

24 November 2003

B-MS ups forecast on strong 3rd quarter

3 November 2003

AstraZeneca's Crestor has beneficial effects on apolipoprotein and lipid ratios

13 October 2003

US FDA/Customs import blitz finds 88% contained unapproved drugs

6 October 2003

Bristol-Myers Squibb warned by FDA over Pravachol ads

18 August 2003

FDA gives tentative approval for IVAX' generic version of Pravachol

11 August 2003

UPDATE: B-MS beats forecasts in 2nd qtr

4 August 2003

B-MS beats forecasts in 2nd qtr

4 August 2003

AstraZeneca's cholesterol-lowerer Crestor gets FDA panel backing

14 July 2003

Tokyo pharma stocks - week to June 30

7 July 2003

Sankyo FY2003 results disappoint, with steep earnings decline forecast in 2004

26 May 2003

Tokyo pharma stocks - week to May 19

26 May 2003

Profits down 11% at B-MS in first quarter

5 May 2003

War, terror and terroism overshadow normally sanguine FDLI meeting

21 April 2003

Update - AstraZeneca 's Crestor: ACC studies

7 April 2003

Sankyo to "dispose of all loss making units"

24 March 2003

UPDATE: B-MS restates $2bn of revenues; closes wholesaler issues

17 March 2003

B-MS restates $2bn of revenues; closes wholesaler issues, profits fall in 2002

17 March 2003

Some TCs poised for Rx-to-OTC switches: new report

24 February 2003

B-MS provides 2003 earnings guidance

27 January 2003

B-MS turnover down 14% in 2nd quarter

29 July 2002

On second try, B-MS gets backing for Pravachol/aspirin combination

29 July 2002

B-MS backed to co-package Pravachol and aspirin

29 July 2002

Mixed results from Japanese pharma companies; forecasts in local price cuts

3 June 2002

Teva gets initial OK for generic Pravachol

27 May 2002

More Zetia trials support efficacy

20 May 2002

AstraZeneca tries to shrug off Crestor delay with new comparative data

13 May 2002

Tokyo pharma stocks - week to April 29

6 May 2002

Bristol-Myers Squibb's earnings sink as generic competition takes hold

6 May 2002

US FDA advisers say no to fixed dose of pravastatin and aspirin from B-MS

28 January 2002

Genaissance completes enrollment in STRENGTH II study.

21 January 2002

New dosage strength for B-MS Pravachol approved

14 January 2002

B-MS earnings driven by Glucophage

24 October 2001

Genaissance begins second STRENGTH study

19 October 2001

Showing 1-100 of 226 articles

Go to beginningPreviousNextGo to end